AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MAYNE PHARMA GROUP LTD

3.030

+0.0301.00%

Volume:68.20K

Turnover:204.16K

Market Cap:248.13M

PE:14.60

High:3.030

Open:3.000

Low:2.970

Close:3.000

52wk High:6.500

52wk Low:2.040

Shares:81.89M

Float Shares:67.00M

Volume Ratio:0.36

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.208

EPS(LYR):0.208

ROE:8.20%

ROA:-1.73%

PB:0.63

PE(LYR):14.60

Loading ...

Overview Company News Filings

BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs

BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs

Mayne Pharma - Entire US Dermatology Generics Portfolio Expected to Be Exempt From Tariffs Under Proclamation

THOMSON REUTERS

Mayne Pharma Group Ltd - Myx Expects No Material Impact From US S232 Tariffs

THOMSON REUTERS

Mayne Pharma Group - Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products

THOMSON REUTERS

Mayne Pharma - Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs

THOMSON REUTERS

Mayne Pharma Group Ltd-Non-Executive Director Retirement and Recruitment

THOMSON REUTERS

Inhibitor Therapeutics sues investor over failed $3 million stock financing

Inhibitor Therapeutics advances itraconazole PK trial for Gorlin syndrome ahead of NDA submission

Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/MYX.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":3.03,"timestamp":1789619882396,"preClose":3,"halted":0,"volume":68196,"delay":0,"changeRate":0.009999999999999934,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"Trading","change":0.03,"latestTime":"09-17 14:38:57 AEST","open":3,"high":3.03,"low":2.97,"amount":204157,"amplitude":0.02,"askPrice":3.03,"askSize":2918,"bidPrice":3.02,"bidSize":3012,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789624800000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":3,"openAndCloseTimeList":[[1789603200000,1789624800000]],"volumeRatio":0.363929,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":3,"auctionPrice":3,"auctionVolume":20664,"auctionTime":1789603143111,"referenceTime":1789554603098,"auction":1,"marketStatus":"盘前竞价","timestamp":1789603143111}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":0.363929,"shares":81890887,"dividePrice":0,"high":3.03,"amplitude":0.02,"preClose":3,"low":2.97,"week52Low":2.04,"pbRate":"0.63","psRate":"0.65","week52High":6.5,"institutionHeld":0,"latestPrice":3.03,"committee":0.015852,"eps":0.207588,"divideRate":0,"volume":68196,"delay":0,"ttmEps":0.207588,"open":3,"prevYearClose":3.11,"prevWeekClose":2.96,"prevMonthClose":3.1,"prevQuarterClose":2.79,"fiveDayClose":3,"twentyDayClose":3.35,"sixtyDayClose":2.39,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625985237","title":"BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625985237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625985237?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:15","pubTimestamp":1775528150,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Expects No Material Impact From Us S232 TariffsApril 7  - Mayne Pharma Group Ltd MYX.AX:MYX EXPECTS NO MATERIAL IMPACT FROM US S232 TARIFFSENTIRE US DERMATOLOGY GENERICS PORTFOLIO EXPECTED TO BE EXEMPT FROM TARIFFS UNDER PROCLAMATIONNO MATERIAL IMPACT EXPECTED FOR MAYNE PHARMA'S WOMEN'S HEALTH PORTFOLIO FROM US S232 TARIFFSSEVERAL OF COMPANY'S BRANDED DERMATOLOGY PRODUCTS MAY BE SUBJECT TO NEW SECTION 232 TARIFFSMINIMAL IMPACT EXPECTED IN SALISBURY, SOUTH AUSTRALIA MANUFACTURING FACILITY AS MOST EXPORT PRODUCTS TO US ARE GENERIC PRODUCTSFurther company coverage: MYX.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625598338","title":"BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625598338","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625598338?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:04","pubTimestamp":1775523848,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs** Mayne Pharma MYX.AX gains as much as 4.7% to A$2.45, highest since April 2** Stock marks biggest intraday pct gain since April 1** Co expects no material impact to FY27 earnings profile from New Section 232 tariff proclamation announced by Donald Trump** Trump signed executive order imposing 100% tariffs on branded pharma products imported into U.S. unless makers agree to government drug pricing deals or commit to making their products domestically** YTD, MYX down 21.5%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q01Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625979600","title":"Mayne Pharma -  Entire US Dermatology Generics Portfolio Expected to Be Exempt From Tariffs Under Proclamation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625979600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625979600?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944600","title":"Mayne Pharma Group Ltd -  Myx Expects No Material Impact From US S232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625944600?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625600102","title":"Mayne Pharma Group -  Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2625600102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625600102?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625460018","title":"Mayne Pharma -  Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625460018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625460018?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624331526","title":"Mayne Pharma Group Ltd-Non-Executive Director Retirement and Recruitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2624331526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624331526?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:33","pubTimestamp":1775093593,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUE1Z01QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624491315","title":"Inhibitor Therapeutics sues investor over failed $3 million stock financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624491315","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624491315?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:08","pubTimestamp":1775074095,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics filed litigation on March 30, 2026 against an institutional investor tied to a failed financing.Transaction contemplated sale of 12,000,000 common shares at $0.25 per share.Financing also included a warrant to buy up to 7,000,000 additional shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibitor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6LspBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","BK4139","INTI","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624550074","title":"Inhibitor Therapeutics advances itraconazole PK trial for Gorlin syndrome ahead of NDA submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2624550074","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624550074?lang=en_us&edition=fundamental","pubTime":"2026-04-01 09:58","pubTimestamp":1775008699,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics outlined progress in a comparative pharmacokinetic clinical study for its proprietary itraconazole formulation in Gorlin syndrome, positioning it as final clinical step before a planned US NDA filing via FDA 505 pathway.Top-line comparative PK and relative bioavailability results will be presented in the future, expected around mid-May 2026, ahead of full clinical study report.Program aims to support more consistent drug exposure versus conventional itraconazole, using an amorphous formulation designed to improve solubility and absorption.Company also plans to file a new global patent application covering formulation composition, targeting stronger IP protection without ongoing royalty obligations if granted.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4cdwxC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","IE00BN0W2W23.USD","BK7096","BK4588","BK7508","SG9999014013.SGD","BK4139","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210149790.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","IE00BN0W2V16.EUR","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00B64PRP62.GBP","INTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622855234","title":"Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855234?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:04","pubTimestamp":1774519475,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics published its annual report on Form 10-K.Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&D activity and developments during the year.General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8NdxCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTI","BK4139","MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":50,"code":"91000000","status":"200"}]}}